Merck Investors Rip Fee Requests In $688M Vytorin Deal

Law360, New York (August 6, 2013, 3:08 PM EDT) -- Investors in two class actions alleging Merck & Co. and its Schering-Plough subsidiary hid test results for their anti-cholesterol drug Vytorin challenged a proposed $688 million settlement of the cases on Monday, saying attorneys' fee requests in the actions were too high.

Class counsel in the Schering-Plough action have asked for $80 million, while counsel in the Merck class action have asked for $60 million. The objectors urged the New Jersey federal court to trim the amounts based on the actual time and effort that counsel...
To view the full article, register now.